JHU-NUS Center for Research on CAMs(Planning Grant)

JHU-NUS CAM 研究中心（规划资助）

基本信息

批准号：
6802395
负责人：
PAUL S LIETMAN
金额：
$ 13.58万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-09-15 至 2006-03-31
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal is a response to an RFA (AT-03-002) from the National Center for Complementary and Alternative Medicine (NCCAM) entitled "PLANNING GRANT FOR INTERNATIONAL CENTERS FOR RESEARCH ON COMPLEMENTARY AND ALTERNATIVE MEDICINE (PICRC)". The unique position of Johns Hopkins in Singapore and the attributes of Singapore itself make Singapore an excellent site for an NIH NCCAM regional International Center for Research on Complementary and Alternative Medicine (ICRC). The proposal is from The Johns Hopkins University School of Medicine in Baltimore and the National University of Singapore and will include collaboration with units in China as well. The Principal Investigator, Paul S. Lietman is a physician-scientist with considerable experience in the organization and leadership of research entities that are focused on clinical research, clinical pharmacology, and the building of an international research unit in Singapore. He and the Singapore Co-Investigator, Eu Leong YONG, also a physician-scientist, have worked closely to assemble a team in Singapore (with JHU collaborators) that could significantly enhance the infrastructure of an embryonic CAM research capacity in Singapore and Southeast Asia. The goal of this proposal will be on the creation of a full-fledged grant application for an International Center for CAM Research (ICRC) in Singapore that includes 3 projects and a core facility. The proposal focuses on several of the most highly significant areas of CAM research, namely: 1. The standardization of TCM products to be studied by plant genomic and biochemical means, the reliable sourcing of herbs and edible plants, and the formulation and manufacturing of products following GMP 2. The development and validation of biomarkers that will facilitate the rigorous study of potentially bioactive herbal and food substances in humans 3. The elucidation of the cancer chemopreventative properties of edible tropical plants 4. The careful and rigorous conduct of clinical research that is essential to prove or disprove the biologic effects of potential therapeutic agents in humans and the clinical studies of interactions of TCMs with commonly prescribed chemotherapeutic agents.

描述（由申请人提供）：该提案是对国家补充医学中心（NCCAM）（NCCAM）的RFA（AT-03-002）的回应，题为“国际互补和替代医学研究中心计划赠款（PICRC）”。约翰·霍普金斯（Johns Hopkins）在新加坡的独特地位以及新加坡本身的属性使新加坡成为NIH NCCAM NCCAM互补和替代医学研究中心（ICRC）的绝佳地点。该提案来自巴尔的摩的约翰·霍普金斯大学医学院和新加坡国立大学，还将与中国的单位合作。首席研究员Paul S. Lietman是一位医师科学家，在研究实体的组织和领导力中拥有丰富的经验，这些研究实体专注于临床研究，临床药理学和新加坡国际研究部门的建设。他和新加坡共同研究者，也是医生 - 科学家欧盟Leong Yong，他密切合作，在新加坡（与JHU合作者）组建一支团队，这些团队可以显着增强新加坡和东南亚的胚胎CAM研究能力的基础设施。该提案的目的是为新加坡国际CAM研究中心（ICRC）创建成熟的赠款申请，其中包括3个项目和一个核心设施。该提案重点介绍了CAM研究中最重要的几个领域，即： 1。通过植物基因组和生化方法研究的TCM产品的标准化，草药和可食用植物的可靠采购以及GMP之后产品的配方和制造 2。生物标志物的开发和验证将促进对人类潜在生物活性草药和食物物质的严格研究 3。阐明食用热带植物的癌症化学预防性特性 4.临床研究的仔细而严格的行为，这对于证明或反驳了潜在治疗剂在人类中的生物学作用以及TCM与普遍处方化学治疗剂的相互作用的临床研究。